ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0552

The Impact of Paricalcitol on Parathyroid Gland Size of Secondary Hyperparathyroidism Patients with Long-Term Maintenance Hemodialysis: An Observational Study

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical


  • Tao, Chenghui, Fengdu People's Hospital, Chongqing, Chongqing, China
  • Liao, Xiaohui, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

This is an observational study to assess effectiveness of paricalcitol for treating secondary hyperparathyroidism (SHPT) patients with long-term maintenance hemodialysis, via changes in biochemical indexes, such as Calcium (Ca), Phosphate (P) and Parathyroid Hormone (PTH), and size of parathyroid gland (PG).


This single-centre and small sample study included 11 Long-term maintenance hemodialysis patients with SHPT, who were undergoing SHPT treatment with paricalcitol in the Blood Purification Centre of Fengdu people’s hospital, Chongqing, China, from December 2018 to October 2019. We Administered Paricalcitol (Zemplar®) intravenously through a hemodialysis vascular access after dialysis as the following dosage: 5 ug tiw for iPTH<1000 pg/ml and 10 ug tiw for iPTH≥500 pg/ml. Titrations based on serum calcium and intact PTH levels.We collected biochemical indexes including Ca, P and iPTH, and imaging parameters of PG via ultrasonography (volume and number), evaluating variations between baseline and Month 11 of post-treatment.


Compared to baseline, the maximum diameter lines of PG decreased significantly (mean 15.727 mm vs 10.936 mm, P=0.005)after 11 months’ treatment, though the minimum diameter lines decreased without statistical difference (mean 6.727 mm vs 5.255 mm, P=0.089). The number of glands was less in Month 11 than that of baseline (mean 2.455 vs 2.182, P=0.277) and iPTH declined significantly (mean 1045.109 pg/ml vs 610.934 pg/ml, P=0.001). The overall effective rate of paricalcitol was 90.9% after 11 months’ treatment. Moreover, there were no significant changes in serum calcium and phosphorus levels during the whole treatment.


Intravenous paricalcitol can decrease the size and number of parathyroid gland, and reduce iPTH concentrations in SHPT patients with Long-term maintenance hemodialysis, without significant influence for serum Ca and P levels.